Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
在携带胚系 BRCA1/2 突变、HER2 阴性的晚期乳腺癌患者中,他拉唑帕尼与化疗的疗效比较:EMBRACA 试验的最终总生存期结果
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2020.08.2098
Litton, J K; Hurvitz, S A; Mina, L A; Rugo, H S; Lee, K-H; Gonçalves, A; Diab, S; Woodward, N; Goodwin, A; Yerushalmi, R; Roché, H; Im, Y-H; Eiermann, W; Quek, R G W; Usari, T; Lanzalone, S; Czibere, A; Blum, J L; Martin, M; Ettl, J